Search

Your search keyword '"O. Chinot"' showing total 283 results

Search Constraints

Start Over You searched for: Author "O. Chinot" Remove constraint Author: "O. Chinot"
283 results on '"O. Chinot"'

Search Results

52. Technical evaluation of thymidine kinase assay in cytosols from breast cancers. EORTC Receptor Study Group Report

55. Subject Index Vol. 66, Suppl. 1, 1996

57. P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting

58. P11.11 Aggressive Meningiomas: In vitro study of the combination pasireotide-everolimus vs. octreotide everolimus

59. OS1.7 Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls

60. High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.

62. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

63. Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.

64. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.

65. TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.

66. Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.

67. Primary central nervous system lymphoma with initial spinal cord involvement (PCNSL-SC) is a rare entity: 4 case reports and review of literature.

68. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial.

69. Prognostic value of Beta 2-Microglobulinin in cerebrospinal fluid in primary central nervous system lymphoma.

70. A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.

71. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms.

72. Primary central nervous system lymphoma (PCNSL) in older patients.

73. Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.

74. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).

75. Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with 68 Ga-DOTATOC PET/CT.

76. Innovative treatments for meningiomas.

77. Contribution of nuclear medicine to the diagnosis and management of primary brain tumours.

78. Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GBM).

79. Association of antidepressant drug use with outcome of patients with glioblastoma.

80. Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.

81. Molecular and clinical diversity in primary central nervous system lymphoma.

82. Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status.

83. Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.

84. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.

85. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.

86. Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH -Mutant Gliomas: A French POLA Network Study.

87. Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma.

88. Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Française (ANOCEF) trial.

89. Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.

90. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.

91. Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.

92. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study.

93. Somatostatin Receptor Theranostics for Refractory Meningiomas.

94. Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma.

95. Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma.

96. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.

97. Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy.

98. Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.

100. [Development of advanced practice nursing in oncology and hematology-oncology in France: Early status report].

Catalog

Books, media, physical & digital resources